


**UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE**

LIMITED RECOGNITION UNDER 37 CFR §10.9(b)

Terrence Lo is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Incyte Pharmaceuticals, Inc. to prepare and prosecute patent applications wherein Incyte Pharmaceuticals, Inc. is the assignee of record of the entire interest in the application filed in the USPTO. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Terrence Lo ceases to lawfully reside in the United States; (ii) Terrence Lo's employment with Incyte Pharmaceuticals, Inc. ceases or is terminated; or (iii) Terrence Lo ceases to remain or reside in the United States on TN status.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: November 18, 2001


Harry I. Moatz
Director of Enrollment and Discipline

"Express Mail" mailing label number EL 856 152 193 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on November, 2001

By: _____ Printed: Nancy Ramos

"Express Mail" mailing label number EL 856 152 193 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on November 16, 2001

By: Nancy Ramos

Printed: Nancy Ramos

Jc542 U.S. PTO
09/991212
11/16/01

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)**

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Dear Sir:

This is a request for filing a **DIVISIONAL** application under 37 CFR 1.53(b) of pending prior U.S. application Serial No. 09/391,958, filed on September 8, 1999, entitled NOVEL HUMAN SODIUM-DEPENDENT PHOSPHATE COTRANSPORTER, which is a divisional application of U.S. application Serial No. 08/805,118, filed February 24, 1997, which issued on November 16, 1999 as U.S. Patent No. 5,985,604, entitled HUMAN SODIUM-DEPENDENT PHOSPHATE COTRANSPORTER.

1. X Enclosed is a specification corresponding to the prior application, U.S. application Serial No. 09/391,958, filed September 8, 1999, which is a divisional application of U.S. application Serial No. 08/805,118, filed February 24, 1997, which issued on November 16, 1999 as U.S. Patent No. 5,985,604, including the oath or declaration as originally signed. The specification does not contain any subject matter that would have been new matter in the prior application.
2. X With regard to the requirement of 37 CFR 1.821(e) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants state that the paper copy of the Sequence Listing for the instant divisional application is identical with the computer readable form filed with U.S. application Serial No. 08/805,118, filed February 24, 1997, which issued on November 16, 1999 as U.S. Patent No. 5,985,604, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with U.S. application Serial No. 08/805,118, filed February 24, 1997, which issued on November 16, 1999 as U.S. Patent No. 5,985,604, as the computer readable form for the instant divisional application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant divisional application.

credit any overpayment to Deposit Account No. 09-0108.

A **duplicate** copy of this Request is enclosed.

10. X New formal drawings are enclosed.
11. X The prior application is assigned of record to Incyte Pharmaceuticals, Inc., recorded on August 11, 1997, at reel 9779/frame 0302.
12. A preliminary amendment is enclosed.
13. X Also enclosed: Return Postcard; Submission of Formal Drawings (2 pp.); Information Disclosure Statement (2 pp.); List of References Cited by Applicants (PTO-1449) (2 pp.); and copy of Limited Recognition Under 37 C.F.R. §10.9(b) (1 pg.).
14. X The power of attorney of the prior application is to:

Narinder S. Banait	Reg. No. 43,482
Adam Warwick Bell	Reg. No. 43,490
Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Colette C. Muenzen	Reg. No. 39,784
Lynn E. Murry	Reg. No. 42,918
Danielle M. Pasqualone	Reg. No. 43,847
Susan K. Sather	Reg. No. 44,316
David G. Streeter	Reg. No. 43,168

- The associate power of attorney in the prior application is to:
- a. X A Revocation of Power of Attorney and Appointment of New Attorneys (2 pp.) is attached.
- b. Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.

"Express Mail" mailing label number EL 856 152 193 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on November 16, 2001

By: Nancy Ramos
Printed: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal and Bandman

Title: NOVEL HUMAN SODIUM-DEPENDENT PHOSPHATE COTRANSPORTER

Serial No.: To Be Assigned Filing Date: Herewith
Examiner: To Be Assigned Group Art Unit: To Be Assigned

Official Draftsman
Commissioner for Patents
Washington, D.C. 20231

SUBMISSION OF FORMAL DRAWINGS

Sir:

Transmitted herewith are Figures 1A, 1B, 1C, 2A, 2B, 3A, 3B and 3C, as eight (8) sheets of formal drawings for this application. Each sheet of drawing indicates the identifying indicia suggested in 37 CFR Section 1.84(c) on the top of the drawings.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.

09091212 111601

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: Nov. 16, 2001

Terence P. Lo

Terence P. Lo

Limited Recognition (37 C.F.R. 10.9 (b)) attached

Direct Dial Telephone: (650) 621-8581

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

099121.11501
TOSTT.21216660